From epigenetics to metastasis: Multifaceted roles of lncRNAs in gastric cancer Authors: Mohamed J Saadh, Ashok Kumar Bishoyi, R Roopashree, K Satyam Naidu, Lokesh Verma, Ojas Prakashbhai Doshi, Piyus Kumar Pathak, Suman Saini, Fadhil Faez Sead Published: 2026 ABSTRACT AbstractGastric cancer (GC) remains one of the leading causes of cancer-related mortality worldwide, largely due to its high metastatic potential and poor prognosis at advanced stages. Epithelial–mesenchymal transition (EMT) is a pivotal biological process that facilitates tumor invasion, dissemination, and therapeutic resistance in GC. In recent years, long non-coding RNAs (lncRNAs) have emerged as critical regulators of gene expression, orchestrating multiple aspects of cancer progression through epigenetic, transcriptional, and post-transcriptional mechanisms. This review provides a comprehensive overview of the current understanding of lncRNA-mediated regulation of EMT and metastasis in gastric cancer. We summarize how lncRNAs function as epigenetic modulators, competing endogenous RNAs (ceRNAs), and molecular scaffolds to regulate EMT-associated transcription factors, signaling pathways, and chromatin dynamics. In particular, key oncogenic pathways such as Wnt/β-catenin, PI3K/AKT, STAT3, and NF-κB are highlighted as major downstream targets of lncRNA activity. Furthermore, we discuss the involvement of lncRNAs in tumor microenvironment remodeling, hypoxia response, angiogenesis, immune regulation, and extracellular matrix reorganization, all of which contribute to metastatic progression. Importantly, dysregulated lncRNA expression is closely associated with clinicopathological features and patient outcomes, underscoring their potential as diagnostic and prognostic biomarkers. In addition, the therapeutic targeting of lncRNAs represents a promising strategy for overcoming metastasis and treatment resistance in gastric cancer. Overall, this review integrates recent advances in the field and provides insights into the complex regulatory networks governed by lncRNAs, highlighting their translational potential in improving GC management.Keywords: Gastric cancer, Long non-coding RNAs, Epithelial-mesenchymal transition (EMT), Epigenetic regulation, Signaling pathways, Angiogenesis Introduction Gastric cancer (GC) remains a significant public health challenge and a leading contributor to cancer-associated morbidity and mortality worldwide [1]. Although its incidence has decreased over recent decades, the global numbers of GC cases and related deaths continue to increase, largely owing to demographic changes such as population growth and aging [1,2]. Recent research has indicated that adhesion, angiogenesis, the extracellular matrix, and cell-to-cell tight junctions all have vital functions in metastasis of GC [3,4]. GC patients should be closely monitored due to the poor prognosis in GC patients in advanced-phase who have received chemotherapy, surgery, or radiation [5]. In recent years, substantial advances have been made in elucidating the molecular pathways driving GC metastasis; however, a comprehensive and coherent mechanistic framework is still lacking [6,7]. As a result, understanding the mechanism of disease and accompanying molecular changes in GC is critical in looking for clinical indicators and treatment strategies [8]. Long non-coding RNAs (lncRNAs), which can function as tumor-suppressive or oncogenic regulators, serve critical roles in these processes [9]. lncRNAs constitute a class of RNA molecules that are primarily transcribed by RNA polymerase II and typically possess a 5′ methylated cap as well as a 3′ polyadenylated tail [10,11]. Based on their genomic localization and transcriptional orientation, lncRNAs are broadly categorized into several groups, including sense, antisense, bidirectional, intronic, and intergenic lncRNAs [12]. Functionally, lncRNAs are key regulators of gene expression, exerting control over the spatial and temporal dynamics of transcriptional programs involved in both normal physiology and disease [13]. These regulatory effects are mediated through diverse molecular mechanisms, which can be classified into five principal modes of action: serving as molecular signals, acting as decoys to sequester regulatory factors, functioning as scaffolds to assemble protein complexes, guiding chromatin-modifying enzymes to specific genomic loci, and operating as SINEUPs to enhance translation of target mRNAs [14]. Although lncRNAs do not encode proteins, they exert important transcriptional and post-transcriptional regulatory functions by modulating gene expression through diverse molecular mechanisms [15]. Because lncRNAs were historically considered nonfunctional transcripts, their biological significance was largely underestimated [16]. lncRNAs have attracted a lot of interest in a variety of fields due to the benefits of genome sequencing technology [17]. Emerging data suggests that lncRNAs do an important part in modulating numerous functions in cells by sponging miRNAs, interacting with proteins, and modulating target gene expression [18]. In gastric cancer, lncRNAs contribute to tumor initiation and progression by modulating gene expression networks that govern cell cycle regulation, cellular proliferation, apoptosis, invasive behavior, metastatic dissemination, and epithelial-mesenchymal transition (EMT) [19,20]. These effects occur at multiple regulatory levels, including epigenetic modification, transcriptional control, and post-transcriptional regulation. Dysregulated lncRNA expression has been consistently associated with clinicopathological features and patient outcomes in gastric cancer, underscoring their promise as diagnostic and prognostic biomarkers [[21], [22], [23]]. Moreover, lncRNAs have emerged as attractive therapeutic targets, as modulation of specific lncRNAs can overcome chemoresistance and improve the responsiveness of gastric cancer cells to anticancer drugs [24]. Notably, lncRNAs modified by N6-methyladenosine (m6A) have been shown to influence the tumor microenvironment and modulate sensitivity to immune checkpoint inhibitors, highlighting their potential utility in predicting and enhancing immunotherapeutic responses in gastric cancer [25]. In this review, we aim to provide a comprehensive and critical overview of the multifaceted roles of lncRNAs in gastric cancer progression, with particular emphasis on their regulation of EMT and metastatic dissemination. This review will discuss the epigenetic, transcriptional, and post-transcriptional mechanisms through which lncRNAs modulate EMT-related programs, oncogenic signaling pathways, tumor microenvironment remodeling, angiogenesis, and immune regulation. Furthermore, it will highlight the potential clinical applications of lncRNAs as diagnostic and prognostic biomarkers, as well as emerging therapeutic targets in gastric cancer. Epithelial-mesenchymal transition (EMT) regulation EMT is a reversible cellular program that enables epithelial cells to acquire mesenchymal characteristics, facilitating migration, invasion, and metastasis. In GC, EMT is tightly regulated by lncRNAs through diverse molecular mechanisms, including epigenetic modulation, competing endogenous RNA (ceRNA) activity, protein scaffolding, and activation of EMT-associated signaling pathways. lncRNAs as epigenetic modulators of EMT Accumulating evidence indicates that lncRNAs play a central role in promoting EMT and metastasis in GC through epigenetic silencing of tumor suppressor genes. For example, HOXA11-AS has emerged as an oncogenic lncRNA, with elevated expression levels associated with advanced disease stage, lymphatic metastasis, and unfavorable clinical outcomes. Liu et al. showed that HOXA11-AS promotes GC cell proliferation and metastasis by modulating chromatin-associated regulatory complexes, leading to transcriptional repression of cell cycle inhibitors and EMT-suppressive genes [26]. These findings highlight a shared mechanism whereby oncogenic lncRNAs hijack epigenetic machinery to silence tumor suppressors and drive EMT-driven metastasis in gastric cancer. Although lncRNAs have traditionally been classified as non-protein-coding transcripts, recent advances in ribosome profiling, ribosome nascent chain complex sequencing, and proteogenomic approaches have revealed that some lncRNAs contain short open reading frames (sORFs) capable of encoding functional micropeptides [27]. These lncRNA-derived micropeptides have emerged as important regulators of cancer biology by modulating signaling pathways, metabolism, angiogenesis, and tumor progression [28]. For example, HOXB-AS3 encodes a 53-amino acid micropeptide that suppresses colorectal cancer progression by interacting with hnRNP A1 and regulating PKM splicing, demonstrating that lncRNA-derived peptides can exert independent biological functions beyond their RNA-mediated effects [29]. Similarly, other lncRNA-encoded micropeptides have been implicated in regulating tumor growth, metabolic adaptation, and therapeutic responses [28]. Although the functional characterization of lncRNA-derived micropeptides in gastric cancer remains limited, emerging evidence suggests that these molecules may represent an unexplored layer of lncRNA-mediated regulation and potential targets for future diagnostic and therapeutic strategies [30]. Beyond single-pathway regulation, some lncRNAs exert dual epigenetic and post-transcriptional control over EMT and tumor progression in GC. For example, SNHG6 has been reported to be markedly upregulated in GC tissues and associated with poor patient prognosis [31]. Mechanistically, SNHG6 promotes GC cell proliferation and EMT by epigenetically silencing the cyclin-dependent kinase inhibitor p27 via chromatin modification, while simultaneously acting as a ceRNA to sponge miR-101-3p, thereby derepressing oncogenic targets involved in EMT progression [31]. This dual-function regulatory mode underscores the complexity of lncRNA-mediated EMT control. Likewise, HOTAIR, one of the most extensively studied oncogenic lncRNAs, is significantly overexpressed in GC and closely linked to metastasis. Zhang et al. demonstrated that HOTAIR promotes GC invasion and metastasis by suppressing poly r(C)-binding protein 1 (PCBP1), a known tumor suppressor involved in RNA stability and translational regulation. Loss of PCBP1 mediated by HOTAIR leads to enhanced EMT marker expression and increased migratory capacity of GC cells [32]. Together, these studies emphasize that lncRNAs can integrate epigenetic repression with RNA regulatory networks to orchestrate EMT and metastatic dissemination in gastric cancer. lncRNAs as ceRNAs in EMT regulation The ceRNA hypothesis has emerged as a fundamental mechanism through which lncRNAs regulate EMT and metastatic progression in GC. By acting as molecular sponges for microRNAs, lncRNAs relieve post-transcriptional repression of EMT-related transcription factors, adhesion molecules, and cytoskeletal regulators [[33], [34], [35]]. This lncRNA-miRNA-mRNA regulatory network enables cancer cells to dynamically modulate EMT programs, thereby enhancing invasion, migration, and distant metastasis [36]. Similarly, Cui et al. reported that FAM230B promotes GC growth and metastasis by sponging miR-27a-5p, leading to increased expression of TOP2A, a gene closely associated with tumor proliferation, genomic instability, and EMT progression. Elevated FAM230B expression was associated with aggressive clinicopathological features, underscoring its oncogenic role [37]. In addition to these lncRNAs, Tian et al. identified GCMA as an SP1-activated lncRNA that drives GC metastasis through its ceRNA activity. GCMA simultaneously sponges miR-124 and miR-34a, two well-established tumor-suppressive miRNAs, resulting in the derepression of EMT-promoting transcription factors such as Slug and Snail [38]. This dual-miRNA sponging mechanism robustly activates EMT programs both in vitro and in vivo, contributing to enhanced metastatic dissemination [38]. Furthermore, Li et al. revealed that UBE2CP3, transcriptionally regulated by ELF3, is abnormally stabilized through RNA–RNA interactions and promotes GC metastasis by acting as a ceRNA for miR-138-5p. This interaction leads to upregulation of ITGA2, an integrin subunit known to facilitate EMT, cell adhesion remodeling, and invasive behavior [39]. Although the CYTOR/miR-136-5p/HOXC10 axis provides a clear mechanistic link to EMT activation, the study primarily relies on in vitro functional assays, and further in vivo validation would be necessary to confirm its clinical relevance in metastatic dissemination. Similarly, SNHG1 was reported to facilitate EMT in GC cells through sequestration of miR-15b, leading to activation of the DCLK1/Notch1 signaling axis [40]. Given the established role of Notch signaling in EMT and cancer stemness, this study strengthens the notion that ceRNA-mediated EMT regulation may intersect with stem-like properties, although the precise contribution of SNHG1 to metastatic colonization remains to be fully elucidated [40]. The EMT-induced lncRNA NR2F1-AS1 represents an example of feedback regulation within EMT programs. This lncRNA is transcriptionally induced during EMT and, in turn, promotes GC progression by sponging miR-29a-3p, thereby enhancing expression of VAMP7, a protein involved in vesicle trafficking and cellular motility [41]. While this axis highlights an underexplored link between vesicular transport and EMT execution, the relatively indirect connection to canonical EMT transcription factors suggests that NR2F1-AS1 may act as a facilitator rather than a primary EMT driver [41]. In contrast, HCP5 has been shown to exert strong EMT-promoting effects under hypoxic conditions, where it sponges miR-186-5p to upregulate WNT5A, linking hypoxia-responsive ceRNA regulation directly to non-canonical Wnt signaling and EMT activation. This context-dependent regulation is particularly noteworthy, as it reflects tumor microenvironment-driven EMT plasticity rather than constitutive pathway activation [42]. THUMPD3-AS1 has been identified as an oncogenic lncRNA that facilitates EMT and invasive behavior in GC through a ceRNA mechanism. Specifically, THUMPD3-AS1 functions as a molecular sponge for miR-1297, thereby relieving post-transcriptional repression of BCAT1. Upregulation of BCAT1 has been associated with enhanced tumor cell migration, invasion, and metabolic reprogramming, processes that are tightly coupled to EMT execution [43]. Functional assays demonstrated that silencing THUMPD3-AS1 suppressed mesenchymal marker expression while restoring epithelial characteristics, whereas its overexpression produced the opposite effect [43]. Moreover, MIR99AHG has been reported to promote GC progression by simultaneously inducing EMT and suppressing apoptotic pathways via ceRNA activity. Mechanistically, MIR99AHG sponges miR-577, resulting in derepression of forkhead box protein P1 (FOXP1), a transcription factor implicated in tumor cell survival, invasion, and mesenchymal transition. Increased FOXP1 expression driven by MIR99AHG leads to reduced epithelial marker expression and elevated levels of EMT-associated mesenchymal markers, accompanied by decreased apoptotic signaling. This dual functional role suggests that MIR99AHG coordinates EMT activation with enhanced cell survival, thereby conferring a selective advantage during tumor progression [44]. SNHG7 is another oncogenic lncRNA that accelerates GC cell migration and invasion by regulating a core EMT transcriptional pathway. SNHG7 exerts its function by acting as a ceRNA for miR-34a, a well-established tumor-suppressive microRNA. Through miR-34a sequestration, SNHG7 increases the expression of Snail, a master EMT transcription factor that represses E-cadherin and drives mesenchymal phenotypic conversion [45]. Activation of the SNHG7/miR-34a/Snail axis results in enhanced EMT marker expression and increased invasive capacity of gastric cancer cells. While this pathway directly connects ceRNA activity to canonical EMT transcriptional control, the broad regulatory scope of miR-34a suggests that SNHG7 may influence multiple oncogenic processes beyond EMT, which should be considered when interpreting its functional impact [45]. lncRNAs as scaffolds for protein complexes Beyond functioning as ceRNAs, an important subset of lncRNAs regulates EMT and tumor progression in gastric cancer by directly interacting with proteins. These lncRNAs act as molecular scaffolds that modulate protein stability, localization, or complex formation, thereby influencing key EMT transcription factors and oncogenic signaling pathways [34,46]. By controlling post-translational events rather than transcriptional or post-transcriptional gene regulation alone, scaffolding lncRNAs provide an additional layer of EMT regulation that is rapid, reversible, and highly context dependent [47]. In this regard, Peng et al. identified MIR31HG as a critical regulator of gastric cancer proliferation and metastasis through its direct interaction with the E3 ubiquitin ligase c-CBL [48]. Mechanistically, MIR31HG facilitates c-CBL-mediated ubiquitination and degradation of β-catenin, a central effector of the Wnt signaling pathway and a key driver of EMT. Loss of MIR31HG resulted in stabilization of β-catenin, enhanced nuclear accumulation, and increased transcription of EMT-related target genes, whereas MIR31HG overexpression suppressed β-catenin signaling and reduced invasive potential. This study highlights an unconventional role for lncRNAs as facilitators of protein degradation, positioning MIR31HG as a negative regulator of EMT through post-translational control of β-catenin signaling [48]. In contrast, DNM3OS has been shown to promote EMT and tumor progression by directly associating with Snail, one of the most potent EMT-inducing transcription factors [49]. Through this interaction, DNM3OS stabilizes Snail and enhances its transcriptional repression of epithelial markers such as E-cadherin, thereby facilitating mesenchymal transition and invasive behavior in gastric cancer cells. This protein-stabilizing function places DNM3OS at the core of EMT transcriptional control [49]. Furthermore, under hypoxic settings, P4HB has been shown to play a vital function in the HIF-1 regulation network and to be directly associated to metastasis and invasion in GC cells [50]. Another example of scaffolding-mediated signaling activation is provided by HOXC-AS1, which promotes gastric cancer progression through direct binding to eukaryotic initiation factor 4A-III (eIF4AIII). This interaction enhances activation of the Wnt/β-catenin signaling pathway, leading to increased EMT marker expression, cell proliferation, and metastatic potential. By linking translational machinery components to oncogenic signaling activation, HOXC-AS1 exemplifies how lncRNAs can function as molecular adaptors that integrate protein synthesis regulation with EMT-associated pathways. However, whether HOXC-AS1 selectively modulates translation of EMT-related transcripts or broadly affects global translation remains to be clarified [51]. Collectively, these studies demonstrate that scaffolding lncRNAs regulate EMT and metastasis in gastric cancer by modulating protein degradation, transcription factor stability, and signaling pathway activation. Unlike ceRNA-mediated mechanisms, these protein-centric interactions enable lncRNAs to exert rapid and potent effects on EMT execution. A key challenge for future research will be to determine how these scaffolding functions intersect with transcriptional and post-transcriptional lncRNA activities to coordinately control EMT plasticity in gastric cancer. lncRNAs regulating EMT-associated signaling pathways EMT is a highly plastic and reversible cellular program that enables epithelial tumor cells to acquire mesenchymal characteristics, thereby promoting migration, invasion, metastatic dissemination, and therapeutic resistance [52]. In gastric cancer, EMT represents a critical driver of tumor evolution and metastatic progression by regulating cell adhesion, extracellular matrix remodeling, and activation of multiple oncogenic signaling pathways [53,54]. Aberrant activation of oncogenic signaling pathways is a central driver of EMT and metastatic dissemination in gastric cancer. Among these pathways, Wnt/β-catenin signaling plays a dominant role in coordinating EMT transcriptional programs, cytoskeletal remodeling, and tumor cell plasticity [55]. Increasing evidence indicates that lncRNAs act as upstream regulators of this pathway, modulating β-catenin stability, subcellular localization, and transcriptional activity. Multiple lncRNAs have been shown to activate Wnt/β-catenin signaling and thereby drive EMT and metastasis in gastric cancer. In this regard, Wang et al. demonstrated that MIR4435-2HG is significantly upregulated in GC tissues and functions as an oncogenic lncRNA by targeting desmoplakin (DSP), a key component of desmosomal junctions that maintains epithelial integrity [56]. Suppression of DSP by MIR4435-2HG leads to destabilization of cell-cell adhesion and stimulation of Wnt/β-catenin signaling, leading to enhanced EMT marker expression, increased cell migration, invasion, and metastatic potential [56]. Consistent with these findings, lncRNA H19 has been identified as a potent EMT regulator that promotes gastric cancer metastasis through activation of Wnt/β-catenin signaling [57]. Liu et al. demonstrated that H19 is highly expressed in GC tissues and cell lines, where its upregulation correlates with increased metastatic capacity. Functional analyses revealed that H19 enhances β-catenin nuclear accumulation and transcriptional activity, leading to downregulation of epithelial markers and upregulation of mesenchymal markers [57]. While this study establishes a strong association between H19 and EMT activation, the precise molecular intermediates linking H19 to β-catenin activation remain incompletely defined, suggesting that H19 may function through multiple upstream regulatory nodes. Beyond EMT induction alone, some lncRNAs coordinate Wnt/β-catenin signaling with additional oncogenic processes. Wu et al. identified SNHG11 as a multifunctional lncRNA that promotes gastric cancer progression by simultaneously activating the Wnt/β-catenin pathway and oncogenic autophagy [19]. SNHG11 enhances β-catenin signaling through post-transcriptional regulation of pathway components while also modulating autophagy-related genes, thereby supporting tumor cell survival under stress conditions. Another lncRNA implicated in Wnt/β-catenin-driven EMT is ZEB2-AS1, which has been reported to contribute to GC tumorigenesis by activating this pathway. ZEB2-AS1 promotes β-catenin signaling and EMT marker expression, thereby facilitating invasive and proliferative phenotypes [58]. Given its antisense relationship with ZEB2, a core EMT transcription factor, ZEB2-AS1 may reinforce EMT programs through both transcriptional and signaling-based mechanisms [58]. While lncRNAs are widely recognized as regulators of EMT progression, increasing evidence indicates that EMT-associated signaling pathways and transcription factors can also regulate lncRNA expression, establishing reciprocal regulatory networks [59,60]. EMT-inducing factors, including ZEB1/2 and SNAIL family members, can transcriptionally regulate specific lncRNAs that further influence tumor progression [61]. For example, FGD5-AS1 has been identified as a ZEB1-regulated lncRNA in gastric cancer, and its expression is closely associated with EMT features, metastasis, and poor prognosis [62]. Similarly, ELF3-AS1 is transcriptionally regulated by SNAI1/SNAI2 and participates in a feedback regulatory loop controlling EMT-related gastric cancer progression [63]. In addition, the TGFβ/SMAD3 pathway, a major EMT-inducing signaling axis, activates TGILR expression, which contributes to gastric cancer invasion and EMT. These findings highlight the bidirectional relationship between EMT regulatory networks and lncRNAs, allowing gastric cancer cells to maintain EMT plasticity and metastatic adaptability [64]. Beyond Wnt/β-catenin signaling, additional pathways such as PI3K/AKT and STAT3-dependent transcriptional programs have emerged as critical regulators of EMT plasticity. lncRNAs modulate these pathways at multiple levels, including transcriptional activation, post-transcriptional regulation, and stabilization of EMT-associated transcription factors, thereby reinforcing invasive and therapy-resistant phenotypes. The PI3K/AKT signaling pathway is a well-established driver of EMT, promoting cytoskeletal remodeling, cell survival, and migratory capacity [65,66]. DLEU2 has been identified as an oncogenic lncRNA that contributes to EMT activation through this pathway. Silencing of DLEU2 markedly suppresses GC cell invasion while reversing EMT marker expression, indicating restoration of epithelial characteristics. Mechanistically, DLEU2 depletion inhibits PI3K/AKT signaling activity, suggesting that DLEU2 functions upstream of this pathway to sustain EMT and invasive behavior [67]. In addition to classical EMT regulation, some lncRNAs integrate EMT with alternative tumor progression mechanisms such as vasculogenic mimicry (VM). PVT1 has been shown to induce aggressive VM formation and promote gastric cancer metastasis through activation of the STAT3/Slug signaling axis [68]. STAT3 activation leads to increased Slug expression, a key EMT transcription factor that represses epithelial markers and enhances mesenchymal traits [69]. PVT1-mediated activation of STAT3 signaling therefore not only drives EMT but also supports VM formation, enabling tumor cells to acquire endothelial-like properties that facilitate nutrient supply and metastatic dissemination [68]. Also, some lncRNAs appear to promote EMT through broader, less pathway-restricted mechanisms. Lnc01614 has been reported to promote GC initiation and progression by activating EMT programs, resulting in enhanced invasion and tumor growth [70]. Collectively, by modulating cell–cell adhesion, β-catenin stability, transcriptional activity, and stress-adaptive processes such as autophagy, lncRNAs enable sustained EMT activation and metastatic progression. A deeper understanding of how these signaling-associated lncRNAs interact and whether they function redundantly or cooperatively will be essential for developing effective anti-EMT therapeutic strategies (Table 1). Table 1Roles of lncRNAs in regulating epithelial–mesenchymal transition (EMT) in gastric cancer.Table 1lncRNAMechanismKey Molecular Targets/PathwaysEMT-Related EffectsClinical/Biological SignificanceRefHOXA11-ASEpigenetic regulationChromatin regulatory complexesEMT activation, proliferationCorrelates with advanced stage and LN metastasis[26]SNHG6Epigenetic + ceRNAp27 silencing; miR-101-3p spongeEMT promotion, proliferationAssociated with poor prognosis[31]HOTAIREpigenetic/RNA regulationPCBP1 suppression↑ EMT markers, invasionStrongly linked to metastasis[32]FAM230BceRNAmiR-27a-5p → TOP2AEMT progression, proliferationAggressive clinicopathological features[37]GCMAceRNAmiR-124/miR-34a → Slug, SnailStrong EMT activationEnhances metastasis in vivo[38]UBE2CP3ceRNAmiR-138-5p → ITGA2EMT, adhesion remodelingPromotes metastasis[39]CYTORceRNAmiR-136-5p → HOXC10EMT, migration, invasionLimited in vivo validation[71]SNHG1ceRNAmiR-15b → DCLK1/Notch1EMT, stemness-associated traitsRole in metastasis needs clarification[40]NR2F1-AS1ceRNA (feedback loop)miR-29a-3p → VAMP7EMT facilitation, motilityInduced during EMT[41]HCP5ceRNA (hypoxia-dependent)miR-186-5p → WNT5AEMT under hypoxiaMicroenvironment-driven EMT plasticity[42]THUMPD3-AS1ceRNAmiR-1297 → BCAT1EMT, invasion, metabolic shiftOncogenic EMT regulator[43]MIR99AHGceRNAmiR-577 → FOXP1EMT + apoptosis inhibitionCoordinates survival and EMT[44]SNHG7ceRNAmiR-34a → SnailCanonical EMT activationMay affect multiple oncogenic pathways[45]MIR31HGProtein scaffoldc-CBL → β-catenin degradationEMT suppressionNegative regulator of EMT[48]DNM3OSProtein scaffoldSnail stabilizationEMT promotionCore EMT transcriptional control[49]HOXC-AS1Protein scaffoldeIF4AIII → Wnt/β-cateninEMT, proliferation, metastasisTranslation–signaling crosstalk[51]MIR4435-2HGSignaling regulatorDSP → Wnt/β-cateninEMT, invasionLoss of epithelial integrity[56]H19Signaling regulatorβ-catenin activationEMT, metastasisMolecular intermediates unclear[57]SNHG11Signaling + autophagyWnt/β-catenin + autophagyEMT, survivalMultifunctional oncogenic lncRNA[19]ZEB2-AS1Signaling regulatorWnt/β-cateninEMT activationReinforces ZEB2-driven EMT[58]DLEU2Signaling regulatorPI3K/AKTEMT, invasionReversal restores epithelial traits[67]Lnc01614Broad EMT regulatorEMT-associated pathwaysEMT, tumor progressionMechanism incompletely defined[70] Roles of lncRNAs in regulating epithelial–mesenchymal transition (EMT) in gastric cancer. Epigenetic regulation Epigenetic dysregulation is a hallmark of gastric cancer, encompassing aberrant DNA methylation, histone modification, chromatin remodeling, and RNA chemical modifications [72]. lncRNAs are increasingly recognized as critical epigenetic regulators, functioning through interactions with DNA, RNA, and epigenetic enzymes to modulate gene expression programs associated with tumor initiation, progression, and metastasis. Functionally, lncRNAs involved in epigenetic regulation can be broadly classified as guides, scaffolds, decoys, or signals, a framework that provides mechanistic insight into their diverse regulatory roles [[73], [74], [75]]. Guide lncRNAs recruit epigenetic modifiers to specific genomic loci, thereby directing chromatin-based gene regulation [76]. In GC, several lncRNAs exert oncogenic or tumor-suppressive effects by guiding DNA methyltransferases or histone-modifying complexes to target genes. SPRY4-IT1 is downregulated in GC tissues and its low expression correlates with larger tumor size, advanced stage, deeper invasion, and lymph node metastasis. DNMT1-mediated methylation appears to regulate SPRY4-IT1 expression, and restoration of SPRY4-IT1 suppresses EMT, indicating that epigenetic silencing of this lncRNA contributes to metastatic progression [77]. Similarly, SNHG17 is significantly upregulated in GC and associated with aggressive clinicopathological features. Mechanistically, SNHG17 binds to the Polycomb Repressive Complex 2 (PRC2) and facilitates EZH2-mediated histone modification at the promoters of p15 and p57, leading to transcriptional repression of these cyclin-dependent kinase inhibitors and enhanced cell cycle progression [78]. It was also reported that NEAT1 functions as an epigenetic guide in GC. ALKBH5-mediated RNA demethylation increases NEAT1 stability, which in turn elevates EZH2 expression and promotes invasion and metastasis. This ALKBH5–NEAT1–EZH2 axis highlights the interplay between RNA methylation and chromatin remodeling in GC malignancy [79]. Recent bioinformatics approaches have facilitated the discovery of clinically relevant lncRNAs in gastric cancer by integrating transcriptomic datasets with functional and survival analyses. For example, WGCNA analysis identified lncRNAs such as CCDC144NL-AS1 and LINC01614 as potential oncogenic regulators associated with poor prognosis and enhanced proliferation, migration, and chemoresistance in GC [80]. Moreover, ceRNA network analyses based on TCGA datasets have revealed complex lncRNA–miRNA–mRNA regulatory axes, including POU6F2-AS2/hsa-miR-137/OPCML, involved in GC progression. These computational strategies provide valuable insights into lncRNA functions and support the identification of potential biomarkers and therapeutic targets [81]. Scaffold lncRNAs serve as molecular platforms that bring together multiple proteins to form functional regulatory complexes [82]. In GC, scaffold lncRNAs coordinate epigenetic enzymes, transcription factors, and ubiquitin-related proteins to regulate tumor-associated pathways [83]. In this regard, DIAPH2-AS1 promotes neural invasion in GC by acting as a scaffold for NSUN2, stabilizing NTN1 mRNA through m5C RNA methylation. Notably, DIAPH2-AS1 protects NSUN2 from ubiquitin-mediated degradation by shielding key lysine residues, thereby sustaining NSUN2 activity and enhancing invasive behavior [84]. Also, BDNF-AS exemplifies a scaffold lncRNA in the context of ferroptosis resistance and peritoneal metastasis. BDNF-AS recruits WDR5 to suppress FBXW7 transcription, leading to impaired ubiquitination of VDAC3. Disruption of this ubiquitin-mediated regulatory axis alters mitochondrial metabolism and promotes ferroptosis resistance in GC peritoneal metastasis [[85], [86], [87]]. Decoy lncRNAs sequester transcription factors, RNA-binding proteins, or ubiquitin-related enzymes, preventing them from interacting with their canonical targets [88]. This mechanism enables indirect yet potent epigenetic and post-translational regulation [89]. For example, lncRNA DRAIC has been identified as a tumor-suppressive epigenetic regulator in GC that functions by modulating protein stability through ubiquitination pathways. Bioinformatic prediction and RNA immunoprecipitation assays revealed that DRAIC directly binds to UCHL5, a deubiquitinase that normally stabilizes NFRKB by removing ubiquitin chains. By competitively binding UCHL5, DRAIC attenuates the interaction between UCHL5 and NFRKB, thereby preventing deubiquitination and facilitating ubiquitin-mediated degradation of NFRKB via the proteasome [90]. This post-translational regulation reduces NFRKB protein levels without affecting its mRNA, highlighting the importance of epigenetic and post-translational control in tumor suppression [90]. This finding aligns with broader evidence linking ubiquitin C-terminal hydrolases (UCHs) to tumorigenesis through dysregulated protein stability [[91], [92], [93]]. CCAT2 functions as a protein-interacting decoy by binding epithelial splicing regulatory protein 1 (ESRP1), thereby modulating CD44 alternative splicing and favoring the production of the oncogenic CD44v6 isoform. This epigenetically regulated splicing shift enhances gastric cancer cell proliferation, migration, and invasion and correlates with unfavorable clinical outcomes [94]. Signal lncRNAs reflect cellular states or environmental cues and modulate transcriptional and epigenetic programs accordingly [95]. Their expression often integrates upstream oncogenic signaling with downstream epigenetic reprogramming. For example, SNHG1 is significantly overexpressed in GC tissues and correlates with tumor stage, lymph node metastasis, microsatellite instability, chromosomal instability, and EBV infection. Its expression positively correlates with DNMT1, suggesting that SNHG1 functions as a signaling lncRNA linking genomic instability to DNA methylation-driven tumor progression [96]. AC093818.1 represents another signal lncRNA that enhances GC metastasis by transcriptionally activating PDK1. By recruiting STAT3 and SP1 to the PDK1 promoter, AC093818.1 activates the AKT/mTOR pathway, thereby promoting EMT and metastatic dissemination [97]. SEMA3B-AS1, in contrast, acts as a tumor-suppressive signal lncRNA. Its overexpression inhibits GC growth and peritoneal metastasis by binding HMGB1 and promoting FBXW7-mediated degradation of BGN via the ubiquitin–proteasome pathway, illustrating how lncRNA signaling can restrain metastatic spread [98]. Microenvironment regulation Modifications in the ECM is one approach of modifying the tumor environment that have a substantial influence on cancer cell activity expose tumor cells to a variety of aberrant circumstances. Dysregulated ECM crosslinking and suppressed stiffness both promote tumor spread and progression [99,100]. Hypoxia represents a critical alteration within the tumor microenvironment that facilitates metastatic progression [101]. This condition is prevalent in most solid malignancies, including gastric cancer, and is strongly associated with increased invasive and metastatic potential [[102], [103], [104]]. Previous research found that numerous hypoxia-related protein-coding genes were connected to GC metastasis and invasion [105]. For instance, recent evidence highlights a critical role for the hypoxia-responsive lncRNA AK123072 in driving GC metastasis. Under hypoxic conditions, AK123072 is markedly upregulated and functions as a key molecular mediator linking hypoxic signaling to epidermal growth factor receptor (EGFR) activation. Mechanistically, AK123072 enhances EGFR signaling cascades, leading to increased migratory and invasive capacities of gastric cancer cells. Activation of the hypoxia/AK123072/EGFR axis contributes to aggressive tumor behavior and underscores the importance of hypoxia-regulated lncRNA networks in gastric cancer progression [106] (Fig. 1). However, Cheng et al. investigated the biological functions of SNHG4 in gastric cancer progression and demonstrated that SNHG4 depletion markedly suppresses GC cell proliferation, migration, invasion, and cell cycle progression. In contrast, SNHG4 overexpression downregulates miR-204-5p while concomitantly upregulating RRM2 expression, thereby promoting malignant phenotypes in gastric cancer cells [107]. MiR-204-5p acts as a tumor suppressor in gastric cancer by targeting multiple oncogenic pathways, including RAB22A, ubiquitin-specific peptidase 47 (USP47), and the epidermal growth factor receptor (EGFR). Through these interactions, miR-204-5p inhibits both tumor cell proliferation and metastatic potential, highlighting its central role in restraining gastric cancer progression [108]. RRM2, the catalytic subunit of ribonucleotide reductase, plays a crucial role in DNA synthesis [109]. Notably, its oncogenic potential in promoting gastric cancer development has been demonstrated in previous studies [[110], [111], [112]]. In addition, AK058003 is a hypoxia-induced lncRNA that Wang et al. found to have a positive relationship with γ-synuclein (SNCG) that both of them are increased under hypoxic conditions in GC cells. SNCG, a synuclein family member, is favorably regulated by AK058003 through methylation and increases metastasis of GC cell [113]. Cancer stem cells (CSCs) represent a distinct subpopulation of tumor cells with self-renewal capacity and contribute to tumor initiation, metastasis, and therapeutic resistance [114]. Increasing evidence indicates that lncRNAs are important regulators of gastric cancer stem cell (GCSC) properties. For example, TSPEAR-AS2 was identified as an oncogenic lncRNA that promotes GCSC stemness by functioning as a ceRNA for miR-15a-5p, leading to upregulation of CCND1 and enhancement of sphere formation, EMT, and tumorigenicity [115]. In addition, epitranscriptomic regulation of lncRNAs has emerged as a novel mechanism controlling GCSC behavior. Site-specific m6A modification of lncRNAs such as PSMA3-AS1 and MIR22HG enhances their stability and promotes GCSC survival and stemness through regulation of miRNA pathways and protein interactions. These findings highlight the importance of lncRNAs and their chemical modifications in maintaining gastric cancer stemness and suggest their potential as therapeutic targets for eliminating CSC populations [116]. Hypoxia-induced lncRNA-mediated regulation of EMT and gastric cancer progression. Under normoxic conditions, hypoxia-inducible factor-1α (HIF-1α) undergoes prolyl hydroxylation, enabling recognition by the von Hippel–Lindau (VHL) E3 ubiquitin ligase complex and subsequent proteasomal degradation. In contrast, hypoxic stress stabilizes HIF-1α, allowing its dimerization with HIF-1β and nuclear translocation, where the complex binds hypoxia-responsive elements (HREs) to activate transcriptional programs associated with tumor progression. Hypoxia-responsive long non-coding RNAs (lncRNAs) integrate into this signaling network through distinct molecular mechanisms. For example, PCGEM1 functions as a scaffold to stabilize the EMT-associated transcription factor SNAI1, leading to repression of E-cadherin and induction of EMT. AK123072 enhances epidermal growth factor receptor (EGFR) phosphorylation, activating the PI3K/AKT signaling cascade and reinforcing hypoxia-driven oncogenic signaling. Additionally, AK058003 promotes metastasis-associated epigenetic remodeling by upregulating γ-synuclein (SNCG) through methylation-dependent mechanisms. As mentioned, lncRNAs are widely recognized to regulate gene expression in cancer through four principal molecular mechanisms: signaling, guiding, scaffolding, and decoy functions. In particular, scaffolding lncRNAs can physically associate with multiple molecular partners, assembling functional complexes that recruit specific signaling components to execute distinct biological processes [117]. In this regard, PCGEM1 functions as a scaffold for SNAI1, a mesenchymal biomarker that acts as a transcription factor to promote EMT. Through this interaction, PCGEM1 promotes cancer cell invasion and metastasis. These findings highlight the hypoxia/PCGEM1/SNAI1 axis as a critical molecular pathway in gastric cancer progression and emphasize the role of hypoxia-responsive lncRNAs in orchestrating metastatic behavior [118]. Furthermore, exosomal transfer of lncRNA PCGEM1 has been shown to enhance GC invasiveness and metastatic potential by stabilizing SNAI1. This mechanism highlights the role of intercellular communication via exosomes in promoting tumor progression and underscores the importance of the PCGEM1/SNAI1 axis in regulating aggressive gastric cancer phenotypes [119]. Additionally, Zhijian Wei et al. showed that the HOTAIR/miR-1277-5p axis regulates the amounts of collagen type V 1 chain (COL5A1), which in turn influences GC tumorigenesis [120]. Additionally, HOTAIR/miR-1277-5p axis regulates the amounts of collagen type V 1 chain (COL5A1), which in turn influences GC tumorigenesis. This finding suggests that the ECM might be a viable GC therapeutic target [120]. Moreover, Gong et al. found LINC01094 as a lncRNA related to late T and N stages and a poor prognosis. According to their findings, LINC01094 enhances GC proliferation and metastasis both in vitro and in vivo. They observed that LINC01094 improves GC migration by binding to AZGP1 [121]. AZGP1 inhibits the progression of cancer by increasing PTEN expression [122,123]. PTEN functions as a negative regulator of the AKT signaling pathway, a central driver of tumor growth, and modulates CCL2 production, thereby influencing the tumor immune microenvironment [124,125]. These findings imply that LINC01094 inhibitors (such as ASOs) might be effective in the treatment of GC. NF-κB is a pivotal transcription factor that drives tumor growth and metastatic progression [126]. By upregulating a range of target genes, NF-κB signaling orchestrates multiple oncogenic processes, including cell proliferation, EMT, invasion, metastasis, and angiogenesis. Its broad regulatory influence underscores the central role of NF-κB in shaping aggressive tumor phenotypes and highlights it as a potential therapeutic target in gastric cancer [[127], [128], [129]]. The immune system relies on NF-κB signaling, which has been related to tumor growth, prognosis, and spread. Various research has demonstrated that lncRNA controls NF-κB and it's downstream signaling pathways. PTEN is a classical tumor suppressor that plays a central role in maintaining the balance of the PI3K/AKT signaling pathway. Through its regulatory effects, PTEN modulates key cellular processes such as proliferation, migration, and angiogenesis, thereby restraining tumor progression [130]. Transcription molecules such as SNAIL, c-Jun, and NF-κB have been demonstrated to block PTEN transcription, and therefore its deficit has been observed in human cancers [131]. Functional studies demonstrate that silencing AK023391 inhibits GC cell proliferation, invasion, and tumor growth while inducing apoptosis and cell cycle arrest, whereas its overexpression enhances these malignant phenotypes. Mechanistically, AK023391 promotes tumorigenesis and invasiveness by activating the PI3K/AKT signaling cascade, which in turn influences downstream effectors including NF-κB, FOXO3a, and p53 pathways to regulate transcription factors implicated in cell survival, proliferation, and invasion [132]. Moerover, lncRNA ANRIL contributes to gastric cancer progression by activating NF-κB signaling. Through this pathway, ANRIL enhances tumor cell proliferation, invasion, and survival, highlighting its role as a key regulator of oncogenic signaling networks in gastric cancer [133]. Moreover, Wei GH et al. discovered that MEG3 is more abundant in neighboring tissue than in GC tissue. Furthermore, MEG3 overexpression increase p53 expression, limiting GC cell proliferation and metastasis [134]. Moreover, LINC00470 is significantly upregulated in GC tissues and cell lines, and its elevated expression correlates with advanced TNM stage, distant metastasis, and poor patient prognosis. Mechanistically, LINC00470 interacts with the m6A methyltransferase METTL3 to modify PTEN mRNA and recruits the m6A reader protein YTHDF2 to promote PTEN mRNA degradation, thereby reducing PTEN expression. Through this epigenetic regulation, LINC00470 diminishes PTEN-mediated tumor suppression, enhancing PI3K/AKT signaling, and promoting gastric cancer cell proliferation, invasion, and metastatic potential [135]. In addition, lncRNA MALAT1 is significantly upregulated in gastric cancer tissues and plasma, and its overexpression enhances proliferation, migration, and invasion of GC cells in vitro by activating the PI3K/AKT signaling pathway. These findings indicate that MALAT1 functions as an oncogenic regulator in gastric cancer progression through modulation of key PI3K/AKT pathway components [136]. Furthermore, lncRNA LINC01537 facilitates GC tumorigenesis and metastasis by stabilizing RIPK4, thereby activating NF-κB signaling. Through this mechanism, LINC01537 enhances cancer cell proliferation, invasion, and survival, highlighting its role as a key regulator of oncogenic NF-κB pathways in gastric cancer [137] (Table 2). Table 2lncRNAs involved in tumor microenvironment regulation and metastasis in gastric cancer.Table 2lncRNAMicroenvironmental contextMolecular mechanismDownstream targets/pathwaysBiological effects in GCRefAK123072HypoxiaHypoxia-induced upregulation; enhances receptor signalingEGFR signaling activationIncreased migration and invasion; enhanced metastatic potential[106]SNHG4Hypoxia-associated signalingceRNA mechanismmiR-204-5p ↓ → RRM2 ↑Promotes proliferation, migration, invasion, and cell cycle progression[107]miR-204-5pTumor suppressive microenvironmentPost-transcriptional repressionEGFR, RAB22A, USP47Inhibits proliferation and metastasis[108]AK058003HypoxiaEpigenetic regulation (methylation)SNCG ↑Enhances metastatic capacity of GC cells[113]PCGEM1Hypoxia/exosomal signalingScaffold lncRNA; stabilizes transcription factorSNAI1 (EMT transcription factor)Promotes EMT, invasion, and metastasis[119]HOTAIRECM remodelingceRNA mechanismmiR-1277-5p ↓ → COL5A1 ↑Alters ECM composition; promotes tumorigenesis[120]LINC01094Tumor–immune microenvironmentProtein bindingAZGP1 ↓ → PTEN ↓ → AKT activationEnhances proliferation, migration, and metastasis[121]AK023391PI3K/AKT–NF-κB signalingPathway activationPI3K/AKT → NF-κB, FOXO3a, p53Promotes tumor growth, invasion, and survival[132]ANRILInflammatory microenvironmentNF-κB activationNF-κB signalingEnhances proliferation, invasion, and tumor survival[133]MEG3Tumor-suppressive microenvironmentTranscriptional regulationp53 ↑Inhibits proliferation and metastasis[134]LINC00470Epigenetic microenvironmentm6A modification scaffoldMETTL3/YTHDF2 → PTEN mRNA degradationActivates PI3K/AKT; promotes invasion and metastasis[135]MALAT1Growth factor–responsive environmentPathway activationPI3K/AKT signalingEnhances proliferation, migration, and invasion[136]LINC01537Inflammatory signalingProtein stabilizationRIPK4 → NF-κB activationPromotes proliferation, invasion, and survival[137] lncRNAs involved in tumor microenvironment regulation and metastasis in gastric cancer. Angiogenesis regulation Endothelial vessel (EV) and vasculogenic mimicry (VM) formation have been proven to feed nutrients to malignancies and support tumor growth. Comparatively to tumors with insufficient vascularization, highly vascular tumors exhibit a greater capacity for metastasis [138]. Metalloproteases (MMPs) frequently play a key role in ECM and vascularization adjustment [139]. Extracellular proteinases, such as MMPs, have been shown to be important modulators of cell-extracellular matrix and cell-cell interaction, therefore maintaining integrity. lncRNA BC002811 promotes GC metastasis by modulating SOX2 binding to the PTEN promoter, leading to reduced PTEN expression. Through this mechanism, BC002811 enhances PI3K/AKT signaling, thereby facilitating tumor cell proliferation, invasion, and metastatic progression [140]. However, MEG3 was found to be down-regulated in GC in vivo and in vitro. However, MEG3 overexpression significantly lowers the increased expression of MMP-2, MMP-9, PCNA, and Ki67 caused by miR-21 mimic. This discovery indicates the regulatory function of the MEG3/miR-21 pathway in GC formation and proposes a viable method for GC therapy [141]. According to Xiaobo Guo et al. there is a significant correlation between the amount of OR3A4 and LNM, distant spread, and invasion. OR3A4 promotes cell invasion and migration (GNB2L1, MACC1, DLX4, NTN4, and PDLIM2), metastasis (DLX4), expansion (MACC1, HOXB7, PIWIL1, DLC-1, GAS6, and GNB2L1), adhesion to cells (PDLIM2, CTNND1, and NTN4), and the progress of the cell cycle (CORO1C) [142]. Moreover, by encouraging VM and angiogenesis, MALAT1, a tumorigenic lncRNA, may encourage metastasis in GC. MALAT1 stimulates β-catenin and E-cadherin expression while boosting p-FAK, p-ERK, and p-paxillin expression. As a result, downstream of p-ERK, MT1-MMP, MMP2, and MMP9 are altered. MALAT1 regulates vasculogenic mimicry and extracellular vesicles by modulating the E-cadherin/β-catenin axis and activating FAK/paxillin and ERK/MMP signaling pathways, thereby promoting cell adhesion remodeling, invasion, and extracellular matrix degradation [143]. The research of Zhen-qiang Wang showed that the lncRNA urothelial carcinoma associated 1 (UCA1) increases the metastatic ability of GC cells in vivo and in vitro via the UCA1/ERK/GRK2/MMP9 pathway. This process is driven by Cbl-c–mediated ubiquitination of GRK2 and activation of the ERK–MMP9 signaling pathway, potentially contributing to angiogenesis [144]. Other signaling regulations In addition to the signaling pathways already discussed, there are other signaling pathways that play a role in the regulation of lncRNAs in GC. For instance, elevated DC-SIGNR promotes liver metastasis of gastric cancer by influencing the expression of the lncRNA HNRNPKP2 through STAT5A, which in turn enhances CXCR4 levels, a chemokine receptor that facilitates directed tumor cell migration and metastatic colonization [145]. GMAN, a lncRNA identified by Wei Zhuo et al. is also enhanced in GC patients and is connected to survival and metastatic development. By competitively interacting with the antisense GMAN, it prevents translation of the ephrin A1 (EFNA1) mRNA [146]. Furthermore, the lncRNA MIAT promotes gastric cancer proliferation and metastasis by regulating the miR-141/DDX5 signaling axis. Through this pathway, MIAT enhances tumor cell growth, migration, and invasive potential, highlighting its role as an oncogenic regulator in gastric cancer progression [147]. DDX5 acts as a transcriptional co-activator for multiple oncogenic transcription factors, thereby driving tumor cell proliferation and metastasis [148]. According to Dandan Li et al. the lncRNA UBE2CP3 is unusually elevated in gastric cancer, resulting in a poor prognosis. UBE2CP3 stimulates tumor development via the miR-138-5p/ITGA2 axis by connecting to the transcription factors ELF3 and IGFBP7. ELF3 suppression and/or IGFBP7 mRNA overexpression in the GC are most likely the causes of the UBE2CP3 imbalance. This suggests that UBE2CP3 might be a therapeutic target in GC [39]. GC is also associated with elevated levels of SNHG3, which correlate with tumor stage and poor survival. By sponging miR-139-5p and inhibiting its normal function, SNHG3 enhances cancer cell invasion, proliferation, and metastasis through upregulation of MYB [149]. By modulating numerous signaling pathways, the MYB transcription factor can impact cell differentiation, survival, and proliferation, making it a crucial mediator of tumorigenesis in numerous tumor types [[150], [151], [152]]. Moreover, elevated levels of heat shock protein 90 alpha family class A member 1 (HSP90AA1) may contribute to disease progression and poor survival in GC patients [153,154]. LncRNA ZNRD1-AS1 is upregulated in gastric cancer and promotes tumor cell proliferation and metastasis by functioning as a ceRNA for miR-9-5p, which leads to increased expression of the miR-9-5p target HSP90AA1. Knockdown of ZNRD1-AS1 suppresses growth and metastatic traits both in vitro and in vivo via the miR-9-5p/HSP90AA1 axis, highlighting its oncogenic role in gastric cancer progression [155]. Furthermore, the lncRNA SNHG15, which has also been associated with a number of malignancies, is over-expressed in GC cell lines and tissues. According to Zhiping Chen et al. inhibiting miR-506-5p restored the effect of suppressing SNHG15 on proliferation, apoptosis, invasion, and migration. The data suggest that SNHG15 may promote cell growth and invasion by decreasing miR-506-5p level [156]. Moreover, C8orf76 has been identified as an oncogenic regulator in gastric cancer, promoting both tumorigenicity and metastatic potential. Mechanistically, C8orf76 directly induces the expression of the lncRNA DUSP5P1, which in turn facilitates cancer cell proliferation, invasion, and dissemination. Elevated activity of the C8orf76/DUSP5P1 axis is associated with poorer patient prognosis, suggesting its potential as both a prognostic biomarker and a therapeutic target. These findings underscore the importance of transcription factor-lncRNA regulatory networks in driving aggressive gastric cancer phenotypes and highlight how dysregulation of such pathways contributes to disease progression [157]. Experimental studies have demonstrated that both 6-mercaptopurine (6-MP) and thiosemicarbazone–Ni complexes significantly downregulated NALT1, LUNAR1, and NOTCH1 expression in Jurkat leukemia cells in a time- and dose-dependent manner, suggesting their potential to modulate oncogenic lncRNA-mediated NOTCH1 signaling [158]. Induced MAPK function has also been linked to enhanced protein expression of important MAPK signaling elements ERK, P38, JNK, and c-Jun [157]. On the other hand, Jinet et al. revealed that greater levels of BCAM and its related lncRNA BAN were associated with GC metastases and a poor prognosis [159]. Furthermore, PVT1 lncRNA has been demonstrated to promote cell proliferation and invasion in vivo and in vitro [160]. Mechanistically, PVT1 promotes tumor progression by physically interacting with forkhead box M1 (FOXM1), a master transcription factor that governs cell cycle progression, proliferation, and metastatic potential in a wide range of malignancies. In GC, aberrant activation of FOXM1 is closely associated with tumor initiation, aggressive growth, metastatic dissemination, and resistance to therapy. FOXM1 exerts these oncogenic effects by transcriptionally activating a network of downstream target genes, including AURKB, SKP2, c-MYC, and CCNB1, which collectively regulate mitotic progression, cell cycle transition, and sustained proliferative signaling. Through its interaction with FOXM1, PVT1 amplifies these transcriptional programs, thereby facilitating GC progression and malignancy [161,162]. Experimental evidence indicates that modulation of lncRNA expression may enhance therapeutic responses in gastric and other cancers. For example, treatment with temozolomide and thiosemicarbazone metal complexes significantly increased CASC2 expression while suppressing AKT expression in glioblastoma cells in a time- and dose-dependent manner, highlighting the potential of lncRNA-targeted strategies to regulate oncogenic signaling and improve anticancer efficacy [163]. Additionally, lncRNA ANCR has been shown to enhance GC invasion and migration by modulating FoxO1 expression. Through this mechanism, ANCR suppresses macrophage M1 polarization in the tumor microenvironment, thereby creating an immunosuppressive niche that favors tumor progression. These findings highlight the dual role of ANCR in promoting both intrinsic cancer cell aggressiveness and extrinsic immune evasion, emphasizing the importance of lncRNA-mediated regulation of tumor–immune interactions in gastric cancer metastasis [164]. Silencing of the oncogenic lncRNA PVT1 enhanced the antitumor activity of paclitaxel in gastric cancer cells by promoting apoptosis, inducing G2/M cell-cycle arrest, suppressing migration, and reducing the expression of drug resistance- and metastasis-related genes, highlighting PVT1 as a promising therapeutic target to overcome chemoresistance in GC [165]. LINC00858 is significantly upregulated in GC and its high expression is associated with poor overall survival. Functional studies show that silencing LINC00858 reduces GC cell migration and invasion in vitro and suppresses metastasis in xenograft models. Mechanistically, LINC00858 directly interacts with the metastasis-associated GTPase RAN and stabilizes its protein expression by inhibiting post-translational ubiquitination, thereby promoting metastatic progression. Transcription factor YY1 binds the LINC00858 promoter to drive its expression in gastric cancer cells, highlighting the YY1/LINC00858/RAN axis as a potential therapeutic target in GC metastasis [166]. Integrated transcriptomic analyses identified STEAP4, EPC1, and CLEC1B as potential non-invasive diagnostic and prognostic biomarkers associated with poor survival in hepatocellular carcinoma [167]. Moreover, integrated bioinformatics and clinical validation identified miR-4443, miR-572, and miR-150-5p as promising circulating biomarkers for breast cancer, demonstrating high diagnostic sensitivity and specificity and supporting the potential of blood-based miRNA profiling for early detection [168]. The Ras-related GTPase RAN is a key regulator of fundamental cellular processes, including cell cycle progression, nucleocytoplasmic transport, and cellular transformation. By controlling the bidirectional trafficking of proteins and RNA between the nucleus and cytoplasm, RAN ensures proper mitotic spindle assembly, chromosome segregation, and nuclear envelope reformation [169]. RAN has been associated with tumor development, metastasis, and bad patient survival in numerous malignancies, such as breast, renal, and GC [170]. However, lncRNA PCAT18 functions as a tumor suppressor in GC by inhibiting proliferation, migration, and invasion through suppression of miR-135b and subsequent upregulation of the tight junction protein CLDN11; overexpression of PCAT18 also reduces tumor growth and metastatic behavior in vivo [171] (Fig. 2). Conversely, microRNA-421 acts as an oncogenic miRNA in GC by targeting CLDN11, thereby promoting cell proliferation, invasion, and metastatic potential in vitro, with higher miR-421 levels observed in tumor tissues and associated with advanced disease features [172] (Table 3). These studies underscore the importance of the PCAT18/miR-135b/CLDN11 and miR-421/CLDN11 axes in regulating gastric cancer progression and highlight how dysregulation of non-coding RNA–mediated control of tight junction components contributes to tumor aggressiveness. lncRNA-mediated regulation of tumor microenvironment and signaling networks in gastric cancer progression. This schematic illustrates representative long non-coding RNAs (lncRNAs) that modulate gastric cancer (GC) progression through transcriptional, post-transcriptional, and tumor microenvironment–associated mechanisms. LOC339059 activates the IL-6/STAT3/c-Myc axis, while lncRNA ANCR regulates FoxO1 signaling, together promoting macrophage polarization toward the pro-tumorigenic M2 phenotype characterized by elevated CD206, CD209, CD163, FIZZ1, and Ym1/2, thereby enhancing cancer cell proliferation. In parallel, multiple lncRNAs function as competing endogenous RNAs (ceRNAs): lncRNA PCAT18 sponges miR-135b to upregulate CLDN11; lncRNA ZNRD1-AS1 regulates the miR-9-5p/HSP90AA1 axis; lncRNA MIAT sequesters miR-141 to increase DDX5 expression; and lncRNA UBE2CP3 modulates the miR-138-5p/ITGA2 pathway. These interconnected signaling cascades within tumor cells and the surrounding microenvironment collectively promote gastric cancer growth, invasion, and overall disease progression. Table 3lncRNAs involved in non-canonical signaling regulation in gastric cancer.Table 3SubsectionlncRNAUpstream regulatorMolecular mechanismKey downstream targets/pathwaysBiological effects in GCRefTranscription factor–driven lncRNA regulatory networksHNRNPKP2DC-SIGNR → STAT5ATranscriptional regulationCXCR4Liver metastasis, directed migration[145]DUSP5P1C8orf76TF-induced lncRNA expressionMAPK signaling (ERK, p38, JNK, c-Jun)Proliferation, invasion, metastasis[157]PVT1FOXM1Protein–lncRNA interactionAURKB, SKP2, c-MYC, CCNB1Cell cycle progression, invasion[[160], [161], [162]]LINC00858YY1Protein stabilizationRAN (inhibition of ubiquitination)Migration, invasion, metastasis[166]UBE2CP3ELF3/IGFBP7Transcriptional dysregulationmiR-138-5p/ITGA2Tumor growth, poor prognosis[39]ceRNA-mediated post-transcriptional regulationMIAT—miRNA spongingmiR-141 ⊣ DDX5Proliferation, migration, invasion[147]SNHG3—miRNA spongingmiR-139-5p ⊣ MYBProliferation, invasion, metastasis[149]ZNRD1-AS1—miRNA spongingmiR-9-5p ⊣ HSP90AA1Growth, metastasis[155]SNHG15—miRNA spongingmiR-506-5pProliferation, invasion, migration[156]PCAT18—miRNA spongingmiR-135b ⊣ CLDN11Suppresses invasion and metastasis[171]miR-421—Post-transcriptional repressionCLDN11Promotes proliferation and metastasis[172]Stress-response and survival signaling pathwaysCellular stressceRNA regulationHSP90AA1Survival, metastasis[[153], [154], [155]]GMAN—Translational inhibitionEFNA1Metastatic progression[146]Cell cycle control, adhesion, and tumor–immune interactionLINC00858YY1Nuclear transport regulationRANCell cycle progression, metastasis[166,169]BANBCAMlncRNA–adhesion axisCell adhesion pathwaysMetastasis, poor prognosis[159]ANCR—Transcriptional modulationFoxO1 → macrophage M1 suppressionInvasion, immune evasion[164] lncRNAs involved in non-canonical signaling regulation in gastric cancer. Conclusion and future perspectives Numerous lncRNAs have been implicated in regulating human biological systems including cell proliferation, metastasis, and apoptosis in GC. It is crucial to understand how lncRNAs are associated with gastric carcinogenesis and progression. By decoding these processes, we may be able to identify potential biomarkers and treatment options to combat GC effectively. Despite substantial progress in elucidating the roles of lncRNAs in gastric cancer metastasis, several critical challenges and opportunities remain. Future studies should prioritize the functional validation of lncRNAs identified through high-throughput profiling by employing robust in vivo models and clinically relevant systems, as many reported mechanisms are still supported predominantly by in vitro evidence. In particular, greater emphasis is needed on dissecting the context-dependent functions of lncRNAs, including their cell type–specific, microenvironment-driven, and stage-specific activities during gastric cancer progression. Advances in epigenomics, single-cell sequencing, and spatial transcriptomics are expected to refine our understanding of lncRNA heterogeneity and regulatory networks within primary tumors and metastatic niches. Integration of multi-omics data will be essential to distinguish driver lncRNAs from passenger transcripts and to clarify how lncRNAs coordinate epigenetic remodeling, EMT plasticity, immune modulation, and metabolic reprogramming. Beyond lncRNA-targeted approaches, future therapeutic strategies may benefit from integrating drug repurposing approaches and emerging anticancer compounds, including GLP-1-based therapies and novel small-molecule inhibitors, which may provide complementary strategies for improving cancer prevention and treatment outcomes [[173], [174], [175]]. Furthermore, the interplay between lncRNA-mediated regulation and RNA chemical modifications, such as N6-methyladenosine, represents an emerging area that warrants deeper investigation due to its potential impact on tumor adaptability and therapeutic responsiveness. From a translational perspective, the development of lncRNA-targeted therapeutics, including antisense oligonucleotides, small interfering RNAs, and CRISPR-based approaches, holds promise but faces substantial obstacles related to delivery efficiency, specificity, stability, and off-target effects. In parallel, rigorous clinical validation is required to establish lncRNAs as reliable biomarkers for prognosis, treatment stratification, and prediction of therapeutic response, particularly in the context of chemotherapy resistance and immunotherapy. CRediT authorship contribution statement Mohamed J. Saadh: Writing – review & editing, Validation, Supervision, Conceptualization. Ashok Kumar Bishoyi: Writing – original draft, Conceptualization. R. Roopashree: Writing – original draft, Methodology, Investigation. K. Satyam Naidu: Writing – original draft, Validation, Data curation. Lokesh Verma: Writing – original draft, Investigation. Ojas Prakashbhai Doshi: Writing – review & editing, Validation, Supervision. Piyus Kumar Pathak: Writing – original draft, Methodology. Suman Saini: Writing – original draft, Investigation. Fadhil Faez Sead: Writing – review & editing, Visualization. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Funding No Funders. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements None. Data availability No data was used for the research described in the article. References Associated Data Data Availability Statement No data was used for the research described in the article.